Kiora strategically invests in research and development to advance its efforts. For the first half of 2023, Kiora reported a reduced net loss of $4.5 million compared to $6.0 million in the first half of 2022, reflecting careful expense management amid progress.

Kiora maintains a strong cash position, ending the second quarter of 2023 with $8.0 million in cash and cash equivalents. The company also has access to a $10 million equity line of credit, of which $9.6 million remains available. In June 2023, Kiora received $1.2 million in research tax credits.

The company has one class of common stock outstanding, totaling 2,024,270 shares as of August 8, 2023. Kiora also has various series of preferred stock that are convertible into additional common shares.

In 2023, Kiora raised $6.3 million by offering common stock, preferred stock, and warrants to support its research and development efforts for rare eye conditions. With careful capital management and access to funding, the company is financially positioned to continue progressing its efforts.

Kiora is led by an experienced management team with proven track records:

Brian M. Strem, Ph.D., President, and CEO, co-founded two companies before Kiora. In addition, he has experience at several others where he focused on business development, corporate strategy, and ophthalmology.

Eric J. Daniels, MD, MBA, Chief Development Officer, has nearly 20 years of experience in companies similar to Kiora. He served as CEO and co-founder of three different companies and has held leadership roles at several others.

Melissa Tosca, CPA, EVP of Finance, has over 20 years of accounting and finance experience, including 15 years at companies like Neomorph and Omniome. She is a Certified Public Accountant.

Stefan Sperl, Ph.D., EVP of CMC and Operations, was previously co-founder and COO of Panoptes Pharma. He has deep industry knowledge through his role in multiple related companies.

This experienced team provides the strategic vision and operational leadership to drive Kiora's success.

Kiora has built a broad patent portfolio protecting inventions across several promising platforms. Their intellectual property reflects a commitment to developing patented innovations that can uniquely support individuals facing vision loss.

Kiora currently holds a robust global patent portfolio with 26 active and valid patents set to expire between 2023-2036. The company's patents provide IP protection for key innovations in its vertical market.

With research continuously ongoing, Kiora actively seeks new patent protections to support advancements in their business. Recent patent applications further strengthen their intellectual property and create long-term opportunities to bring new technologies to people facing vision loss.

San Diego has developed into one of the world's largest hubs for life sciences companies, second only to Boston/Cambridge. Over 900 enterprises, from large companies to emerging startups, research organizations, and support services, are located in San Diego.

Significant life science companies have operations in San Diego, and dozens of smaller companies are also headquartered there.

This concentration exists because San Diego is home to prestigious institutions, including UC San Diego, Scripps Research, Salk Institute, and Sanford Burnham Prebys. This dense talent pipeline attracts companies. The area also offers a high quality of life, drawing top scientists and executives. The ecosystem enables fruitful collaborations for startups through networking.

For an emerging company like Kiora, being based in San Diego provides valuable access to partners, academic collaborators, industry experts, and life science investors. The cluster of interconnected companies accelerates innovation, recruitment, and funding. San Diego's culture also promotes the entrepreneurial spirit leading to breakthroughs.

Kiora's location provides strategic advantages, talent and resources, and positioning at the heart of bioscience advancement.

This communication is neither an offer to sell nor a solicitation of an offer to buy, nor a recommendation of any securities of the company mentioned herein.

Kiora Pharma, Inc.  (the “Company”) has reviewed the content of this page as well as the accompanying presentation (“Company Presentation”) displayed on this page. To the best of its knowledge, the Company does not believe this content to be misleading or inaccurate in any material respect, nor does it believe there are any material omissions with respect to such content. The Company does not believe the contents of the page or the Company Presentation to contain any non-public material information.

Information and opinions presented in the Company Presentation are provided by the Company, and b2iDigital makes no representation as to their accuracy or completeness. The information contained on this page is not intended to constitute any form of advice, and the information provided is not intended to provide a sufficient basis on which to make an investment decision. It is not investment research, nor does it constitute a research recommendation, as it does not constitute substantive research or analysis. This information is not to be relied upon in substitution for the exercise of independent judgment. 

Information, opinions and estimates contained on this page or in the Company Presentation reflect judgments by the Company as of the original date of publication by the Company and are subject to change without notice. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance.

A complete description of the risks and uncertainties relating to the Company and its securities can be found in the company's filings with the U.S. Securities and Exchange Commission available for free at www.sec.gov.

Information on this page may relate to penny stocks, which may also be referred to as low-priced stocks. Penny stocks are low-priced shares typically issued by small companies. Penny stocks involve greater than normal risk, they may be less liquid than other stocks (i.e., more difficult to sell), and there may be less reliable information available regarding such stocks. Investors in penny stocks should be prepared for the possibility that they may lose their entire investment.

b2i digital or its related entities may own securities of the Company.

The Company is a client of b2i Digital. The Company agreed to pay b2i Digital no greater than $100,000 in cash for 12 months of digital marketing consulting and investor awareness services.

This communication includes forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believes,” “hopes,” “intends,” “estimates,” “expects,” “projects,” “plans,” “anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Company’s forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks, uncertainties and other factors. The Company urges readers to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this communion. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this communication.